Dermala’s patented technology uses novel, human microbiome-derived postbiotics, metabolites derived from beneficial bacteria in the human microbiome, that inhibit acne-causing C. acnes bacteria, including antibiotic-resistant clinical isolates from individuals with treatment-resistant acne. These beneficial postbiotics act synergistically when combined with other ingredients currently approved for treating acne. As a result, the combinations significantly increase the treatment efficacy without causing side effects, said the company. In addition, these microbiome-derived postbiotics correct the imbalance in the microbiome of individuals with acne and strengthen the acne-fighting bacteria present in the skin microbiome thus producing longer-lasting results naturally.
"The consumer dermatology is ripe for science-based solutions to treat common skin conditions," said Lada Rasochova, Ph.D., MBA, founder/CEO and the patent co-inventor. “Using the human microbiome to treat skin conditions associated with microbiome imbalances makes great scientific sense. We've demonstrated that we can deliver superior results by incorporating the human microbiome in a novel, unique, and unexpected way."